Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ACTRN12626000137392) titled 'Study to Evaluate the Maximum Tolerated Dose and Analgesic Effect Of CT2000' on Feb. 4.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Masking: Blinded (masking used)
Primary Sponsor: Channel Pharmaceutical Corporation Pty, Ltd
Condition:
Dry Eye Disease
Dry Eye Disease
Eye - Diseases / disorders of the eye
Intervention:
This is a Phase 1b/2a randomized, double-masked, vehicle as placebo-controlled study evaluating ocular tolerability, safety, and efficacy of CT2000 (10 mg/mL, 12.5 mg/mL and 15 mg/mL) for ocular pain as a function of moderate to sever...